Although immunotherapy has provided a therapeutic revolution in the management of several types of malignant neoplasms, the incidence of irAEs during extensive use of PD-1/PD-L1 blockade is increasing; thus, a precise strategy using systemic steroids to treat irAEs is required. Here, CD274 is linked to cancer.